On May 7, 2020, Entos Pharmaceuticals announced a partnership with PrecisionNanoSystems (PNI) to produce clinica lgrade vaccines and therapeutics using PNI’s NanoAssemblr GMP System.

Entos will incorporate PNIﾒs NanoAssemblr GMP System into the manufacturing suite at the Alberta Cell Therapy Manufacturing Facility, located in the University of Alberta. This will enable the production of clinical grade Fusogenix genetic nanomedicines such as Covigenix, Entos’s pan-coronavirus Fusogenix DNA vaccine.